2018
DOI: 10.1136/dtb.2018.2.0587
|View full text |Cite
|
Sign up to set email alerts
|

Kyleena – another levonorgestrel IUS

Abstract: A levonorgestrel (LNG) intrauterine system (IUS) known as Kyleena (Bayer PLC) received marketing authorisation from the European Medicines Agency in 2016. The device contains 19.5mg LNG and is licensed for contraception for up to 5 years. This is the fourth LNG IUS product to be licensed for use in the UK. The company states that Kyleena offers advantages over Mirena and Jaydess LNG IUS devices. Here we consider the evidence for Kyleena.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 3 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?